



Acacia Ridge QLD 4110

Tel: +61 (0)7 3370 6396 Fax: +61 (0)7 3370 6370 Website: www.agenix.com

Australia

7 Durbell Street P.O. Box 391

082-34639



SUPPL

7 November 2007

US Securities and Exchange Commission Attention: Filing Desk 450 Fifth Street NW **WASHINGTON DC 20549 USA** 

Dear Sir

Re: Submission Under Rule 12g3-2(b) - Agenix Limited

We refer to the attached announcement that was made to the Australian Stock Exchange on 07 November 2007.

We are providing a copy of the announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely

Erica Headlam Assistant Accountant



## COMPANY ANNOUNCEMENT CHANGE TO DATE OF ANNUAL GENERAL MEETING

The Company's Annual General Meeting of Agenix has been postponed and will now be held at 10.00am (Brisbane time) on Tuesday 11 December 2007 in the Surveyors Room, Conrad Treasury Hotel, Brisbane.

As announced to ASX on 1 November 2007, the Annual General Meeting was to be held on 27 November 2007.

However, the external mailing house misdirected the Notice of Meeting and the accompanying Annual Report so that shareholders have not received those documents.

The replacement Notice of Meeting and the Annual Report will be dispatched tomorrow, Thursday 8 November 2007.

The Australian Securities and Investments Commission has consented to the extension of time to hold the Annual General Meeting.

If you have any queries please contact Karl Schlobohm, Agenix Company Secretary, on 0419 721 007.

Karl Schlobohm Company Secretary

Klalolol

7 November 2007

## For more information about Agenix, please contact:

Mr Neil Leggett CEO and Managing Director Agenix Limited Ph: 61 7 3370 6310

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY] is a biotechnology company based in Brisbane, Australia. Through its wholly owned subsidiaries, Agen Biomedical Ltd and Agenix Biopharmaceutical (Shanghai), the company has a strategic goal of building and developing a pipeline of therapeutic and imaging products.

END